Critical review of resveratrol in xenobiotic-induced hepatotoxicity. (December 2015) - McGill, Mitchell R.
Abstract: Use of natural products is increasingly popular. In fact, many patients with liver diseases self-medicate with herbal supplements. Resveratrol (RSV), in particular, is a common natural product that can reduce injury in experimental models of liver disease. Xenobiotic hepatotoxicity is a particularly important area-of-need for therapeutics. Drug-induced liver injury, for example, is the most common cause of acute liver failure (ALF) and ALF-induced deaths in many countries. Importantly, RSV protects against hepatotoxicity in animal models in vivo caused by several drugs and chemicals and may be an effective intervention. Although many mechanisms have been proposed to explain the protection, not all are consistent with other data. Furthermore, RSV suffers from other issues, including limited bioavailability due to extensive hepatic metabolism. The purpose of this article is to summarize recent findings on the protective effects of RSV in xenobiotic-induced liver injury and other forms of liver injury and to provide a critical review of the underlying mechanisms. New mechanisms that are more consistent with data emerging from the toxicology field are suggested. Efforts to move RSV into clinical use are also considered. Overall, RSV is a promising candidate for therapeutic use, but additional studies are needed to better understand its effects. Highlights: Resveratrol has been shown to protect against many hepatotoxicants. The most commonly proposed mechanisms are antioxidant and anti-inflammatory effects. The proposed mechanisms are not always consistent with data from related studies. Where possible, we suggest the most likely mechanisms of protection based on all available data. Resveratrol may be useful to treat liver disease, but mechanisms are unclear and bioavailability is an issue.